CareDx (CDNA) – Analysts’ Weekly Ratings Updates

CareDx (NASDAQ: CDNA) recently received a number of ratings updates from brokerages and research firms:

• 3/3/2025 – CareDx had its price target lowered by analysts at HC Wainwright from $26.00 to $25.00. They now have a “neutral” rating on the stock.
• 2/27/2025 – CareDx had its “overweight” rating reaffirmed by analysts at Stephens. They now have a $40.00 price target on the stock.
• 2/26/2025 – CareDx was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 2/18/2025 – CareDx was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 1/15/2025 – CareDx was upgraded by analysts at Wells Fargo & Company from an “underweight” rating to an “equal weight” rating. They now have a $24.00 price target on the stock, down previously from $28.00.
• 1/14/2025 – CareDx had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.

CareDx Stock Performance

Shares of CDNA stock traded down $0.83 during mid-day trading on Tuesday, reaching $20.30. 1,251,973 shares of the company were exchanged, compared to its average volume of 844,482. The business’s 50 day simple moving average is $22.70 and its 200 day simple moving average is $25.14. The company has a market capitalization of $1.09 billion, a P/E ratio of -7.52 and a beta of 1.87. CareDx, Inc has a fifty-two week low of $7.42 and a fifty-two week high of $34.84.

CareDx (NASDAQ:CDNA) last posted its earnings results on Wednesday, February 26th. The company reported $1.51 EPS for the quarter, beating the consensus estimate of $0.05 by $1.46. The firm had revenue of $86.58 million for the quarter, compared to analysts’ expectations of $84.56 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. On average, analysts forecast that CareDx, Inc will post -0.9 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CDNA. Creative Planning acquired a new stake in shares of CareDx during the 3rd quarter valued at about $204,000. Hanseatic Management Services Inc. acquired a new stake in CareDx during the third quarter valued at approximately $781,000. Principal Financial Group Inc. bought a new stake in shares of CareDx in the 3rd quarter valued at approximately $557,000. KBC Group NV bought a new stake in shares of CareDx in the 3rd quarter worth about $99,000. Finally, Royce & Associates LP increased its position in shares of CareDx by 0.3% during the 3rd quarter. Royce & Associates LP now owns 393,286 shares of the company’s stock worth $12,280,000 after purchasing an additional 1,000 shares in the last quarter.

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.